Bimekuzumab, a monoclonal antibody developed by UCB SA, has achieved superior skin clearance in a Phase 3 trial of patients with plaque psoriasis compared adalimumab (Humira), a standard of care for the disease. Data from the study were presented at the European Academy of Dermatology and Venereology Congress on 31 October.
